AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24344672
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose antibiotic impregnated cement (1 gram Clindamycin and 1 gram Gentamicin)
Trial: 19090407
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) injection (5 microg in 0.2 mL)
Trial: 19090407
Drug: Buffered isotonic
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered isotonic saline (control, 0.2 mL)
Trial: 9387731
Drug: Tangshenkang (TSK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangshenkang (TSK) capsule
Trial: 1415946
Drug: Oral examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral examination performance (grouped as honors, high satisfactory, satisfactory, unsatisfactory)
Trial: 1415946
Drug: Oral examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral examination groups throughout the rotations
Trial: 2991478
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus methanol extractable residue of BCG (MER-BCG)
Trial: 30010061
Drug: Colistin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin monotherapy (loading dose of 9 MIU followed by 3 MIU every 8 hours)
Trial: 30010061
Drug: Colistin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin + meropenem combination therapy (colistin 8.58 MIU and meropenem 1 g every 8 hours for 15 days)
Trial: 21357882
Drug: Internet-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioural therapy (CBT)
Trial: 23829297
Drug: Multispecies probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies probiotics (Bifidobacterium longum, B. bifidum, B. lactis, Lactobacillus acidophilus, L. rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks
Trial: 21775910
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 4 weeks
Trial: 9656503
Drug: Lamaze preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamaze preparation
Trial: 7625503
Drug: Spermicidal suppositories
RxNorm normalized name: lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermicidal suppositories
Trial: 7625503
Drug: Foaming tablets
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foaming tablets
Trial: 2464094
Drug: Dilevalol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol (400 mg)
Trial: 321184
Drug: oxpentifylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxpentifylline (200 mg 3-times a day)
Trial: 30852939
Drug: MEDI7510 (adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI7510 (adjuvanted RSV sF vaccine)
Trial: 27567020
Drug: Orbital Atherectomy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital Atherectomy System (OAS) treatment in patients with eGFR < 90 ml/min/1.73 m2
Trial: 27567020
Drug: Orbital Atherectomy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital Atherectomy System (OAS) treatment in patients with eGFR ≥ 90 ml/min/1.73 m2
Trial: 23547848
Drug: Tocilizumab 162
RxNorm normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 162 mg (s.c.)
Trial: 23547848
Drug: Tocilizumab 81
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 81 mg (s.c.)
Trial: 21736720
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care program (watchful waiting, guided self‐help, short face‐to‐face problem solving treatment, pharmacotherapy and/or specialized mental health care)
Trial: 10986540
Drug: ACE chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE chemotherapy plus G‐CSF (granulocyte colony‐stimulating factor) at 2‐week intervals
Trial: 10986540
Drug: ACE chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE chemotherapy alone at standard 3‐week intervals
Trial: 9076616
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg) three times daily for 4 weeks
Trial: 9076616
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily for 4 weeks
Trial: 8401051
Drug: Trimethylamine oral
RxNorm normalized name: trimethylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethylamine oral challenge (600 mg)
Trial: 3045026
Drug: Defibrotide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (200 mg/day, intramuscular)
Trial: 28377492
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT (LDCT) screening for lung cancer, annual invitation for 4 years
Trial: 28377492
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT (LDCT) screening for lung cancer
Trial: 23715925
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g intravenously 15-45 min before skin incision
Trial: 11050580
Drug: Isotretinoin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (1 mg/kg) + Vitamin E (800 IU/day)
Trial: 11050580
Drug: Isotretinoin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (1 mg/kg) + Vitamin E placebo
Trial: 8265524
Drug: Erythromycin with
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin with midazolam 5 mg
Trial: 8265524
Drug: Midazolam 10
RxNorm normalized name: midazolam 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 10 mg with erythromycin
Trial: 8265524
Drug: Midazolam 10
RxNorm normalized name: midazolam 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 10 mg with roxithromycin
Trial: 2872056
Drug: diacetolol 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacetolol 600 mg
Trial: 2879477
Drug: acebutolol 400
RxNorm normalized name: acebutolol 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol 400 mg
Trial: 2872056
Drug: metoprolol 200
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 200 mg
Trial: 1687425
Drug: propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol 80 mg
Trial: 25397825
Drug: Acupuncture (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (8 sessions of 60 minutes each, twice weekly)
Trial: 22915053
Drug: Temozolomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (200 mg/m² on days 1-5) and Bevacizumab (10 mg/kg on days 1 and 15) every 28 days (Regimen TB)
Trial: 22915053
Drug: Nab-paclitaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (100 mg/m² or 80 mg/m² post-addendum on days 1, 8, and 15), Bevacizumab (10 mg/kg on days 1 and 15), and Carboplatin (AUC 6 on day 1 or AUC 5 post-addendum) every 28 days (Regimen ABC)
Trial: 20860546
Drug: ABX‐IL8 (fully
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX‐IL8 (fully human IgG₂ monoclonal antibody)
Trial: 16647911
Drug: Metronidazole vaginal
RxNorm normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole vaginal gel (0.75%)
Trial: 2339625
Drug: 1,25‐(OH)2D3 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25‐(OH)2D3 2 micrograms/day for 2 weeks before 3 months of sodium fluoride treatment 25 mg twice a day, in each 5‐month cycle
Trial: 2339625
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (NaF) 25 mg twice a day with 1,25‐(OH)2D3 0.5 micrograms/day for 12 months in each 13‐month cycle
Trial: 2339625
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including sodium fluoride treatment)
Trial: 2339625
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride treatment
Trial: 6109465
Drug: Flunitrazepam (0.4‐0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.4‐0.8 mg)
Trial: 6109465
Drug: Benzoctamine (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoctamine (10‐20 mg)
Trial: 16218045
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene (RLX) 60 mg/die
Trial: 9740203
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of zinc (1200 microg/kg, ratio 4:1)
Trial: 9740203
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of zinc (300 microg/kg, ratio 1:1)
Trial: 8037087
Drug: Intravenous isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isosorbide dinitrate (ISDN) infusion at 10 to 60 micrograms/min for 1 hour, 2 days, or 5 days
Trial: 8037087
Drug: Intracoronary isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary isosorbide dinitrate (ISDN) bolus (1 mg)
Trial: 28969715
Drug: Annual treatment
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual treatment with IVM + ALB
Trial: 28969715
Drug: Biannual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual treatment with IVM + ALB (annual MDA followed by an additional MDA 6 months later)
Trial: 24029871
Drug: Regular sodium
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular sodium diet (194±49 mmol Na/day) with lisinopril (40 mg/day)
Trial: 24029871
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (102±52 mmol Na/day) with lisinopril (40 mg/day)
Trial: 24029871
Drug: Regular sodium
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular sodium diet (194±49 mmol Na/day) with lisinopril plus valsartan (320 mg/day)
Trial: 24029871
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (102±52 mmol Na/day) with lisinopril plus valsartan (320 mg/day)
Trial: 15187504
Drug: AVP/NE infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP/NE infusion (4 units/hr)
Trial: 15187504
Drug: NE infusion
RxNorm normalized name: Ne
DrugBank: Neon (DB11589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NE infusion only
Trial: 15187504
Drug: AVP/NE infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP/NE infusion
Trial: 9065344
Drug: Triprolidine hydrochloride
RxNorm normalized name: Triprolidine Hydrochloride
DrugBank: Triprolidine (DB00427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triprolidine hydrochloride 5 mg
Trial: 8091379
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dermatan sulfate (MF701) b.i.d.
Trial: 8091379
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dermatan sulfate (MF701) b.i.d.
Trial: 8091379
Drug: Both dosages
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosages of dermatan sulfate (100 mg and 300 mg)
Trial: 2517718
Drug: Prazosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin therapy for one week
Trial: 2517718
Drug: Prazosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin therapy during hyperosmolar mannitol load
Trial: 2517718
Drug: Prazosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin therapy
Trial: 1097597
Drug: Electrosleep treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrosleep treatment (24 live treatments)
Trial: 30711664
Drug: Active online
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active online cognitive behavioral therapy (iCBT) intervention with EFI
Trial: 30711664
Drug: Active online
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active online cognitive behavioral therapy (iCBT) intervention without EFI
Trial: 26495881
Drug: Modified Dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Dual Therapy (MDT) with amoxicillin 750 mg thrice daily plus rabeprazole 20 mg thrice daily
Trial: 26495881
Drug: Standard Quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Quadruple Therapy (SQT) with rabeprazole 20 mg b.i.d., bismuth subcitrate 120 mg q.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d.
Trial: 26495881
Drug: Standard Quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Quadruple Therapy (SQT)
Trial: 22950390
Drug: Phenylephrine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine at a dose of 0.3-0.4 μg.kg(‐1).min(‐1)
Trial: 22950390
Drug: Dopamine and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine and/or dobutamine at 2-8 μg.kg(‐1).min(‐1)
Trial: 16188156
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - 80 mg in one dose
Trial: 16188156
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B - repeated epirubicin 40 mg q wk x 4-8 sessions followed by q month to the end of the second year
Trial: 16188156
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C - 50 mg q month to the same duration
Trial: 2704341
Drug: Recent aggressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recent aggressive treatment protocols for ALL
Trial: 2704341
Drug: Three-drug reinduction
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug reinduction program after consolidation
Trial: 408433
Drug: H. influenzae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. influenzae type b polysaccharide vaccine
Trial: 408433
Drug: N. meningitidis
RxNorm normalized name: N. MENINGITIDIS VACC (TRUMENBA) SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. meningitidis polysaccharide vaccine
Trial: 30653086
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg elemental selenium daily)
Trial: 27922453
Drug: Fostemsavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (400 mg twice daily)
Trial: 27922453
Drug: Fostemsavir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (800 mg twice daily)
Trial: 27922453
Drug: Fostemsavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (600 mg once daily)
Trial: 27922453
Drug: Fostemsavir (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (1,200 mg once daily)
Trial: 27922453
Drug: Fostemsavir (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostemsavir (various doses)
Trial: 27922453
Drug: ATV/r (ritonavir-boosted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/r (ritonavir-boosted atazanavir 300/100 mg once daily)
Trial: 24571193
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg methylnaltrexone
Trial: 21646646
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily for 6 months
Trial: 19888785
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (valsartan/HCTZ)
Trial: 16920896
Drug: Tesaglitazar 1
RxNorm normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesaglitazar 1 mg during fasting
Trial: 16920896
Drug: Tesaglitazar 1
RxNorm normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesaglitazar 1 mg after a high-fat, high-calorie breakfast
Trial: 9261306
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with aqueous humor suppressants (n = 11)
Trial: 9261306
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (n = 11)
Trial: 24173028
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR vaccine (single oral dose of ∼4.4 × 10(8) CFU)
Trial: 19459475
Drug: Grifor vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grifor vaccine
Trial: 7597114
Drug: Alprazolam 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1.0 mg
Trial: 19052126
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 10 mg once daily for 48 weeks
Trial: 10947322
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (200 micrograms twice daily) via Pulvinal inhaler
Trial: 10947322
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (200 micrograms twice daily) via Diskhaler inhaler
Trial: 8874327
Drug: 5‐FU 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 450 mg/m2 as an intravenous bolus with FA 200 mg/m2 in 500 mL 0.9% normal saline solution in 2‐hour infusion (Group A)
Trial: 8874327
Drug: 5‐FU 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 450 mg/m2 as an intravenous bolus with FA 200 mg/m2 in 500 mL 0.9% normal saline solution in 2‐hour infusion plus IFN 2b 5 million units subcutaneously three times weekly (Group B)
Trial: 30071993
Drug: Ranolazine 1,000
RxNorm normalized name: Ranolazine 1,000mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 1,000 mg twice a day
Trial: 28777224
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg intracameral bevacizumab
Trial: 25493621
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution as placebo
Trial: 18032884
Drug: Cocoa powder
RxNorm normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa powder dissolved in water (CC-W)
Trial: 18032884
Drug: Cocoa powder
RxNorm normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa powder dissolved in milk (CC-M)
Trial: 11784454
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg daily for 12 weeks)
Trial: 23624993
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 12 weeks)
Trial: 12209299
Drug: Lichtenstein patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lichtenstein patch
Trial: 3061823
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/mq i.v. every 3 weeks) + 5‐fluorouracil (600 mg/mq i.v. bolus/weekly)
Trial: 26218236
Drug: PREG-LT (Pregnenolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PREG-LT (Pregnenolone 50 mg/day + L-Theanine 400 mg/day)
Trial: 27701170
Drug: Beta-blockers (BBs)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (BBs) at baseline
Trial: 27701170
Drug: Ceftriaxone (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (intravenous, 2 g per day for 4 days)
Trial: 23995395
Drug: Post-treatment (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (3 months after acute phase)
Trial: 19020155
Drug: Ketamine (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (infusion of 15 microg x kg(‐1) x min(‐1))
Trial: 19020155
Drug: Ketamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine and fentanyl (infusion of 15 microg x kg(‐1) x min(‐1) ketamine plus three bolus of 1 microg x kg(‐1) fentanyl)
Trial: 19020155
Drug: Lornoxicam (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (one bolus of 8 mg)
Trial: 19020155
Drug: Lornoxicam and
RxNorm normalized name: Lornoxicam and paracetamol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam and fentanyl (one bolus of 8 mg lornoxicam plus three bolus of 1 microg x kg(‐1) fentanyl)